Canertinib Dihydrochloride

盐酸卡奈替尼

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameCanertinib Dihydrochloride
Drug Alias Name盐酸卡拉替尼canertinibum盐酸卡奈替尼卡纽替尼二盐酸盐卡奈替尼 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksKEGG